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Abstract
Chronic lymphocytic leukemia (CLL) remains incurable with current standard therapy.
We have previously reported that an increased expression of interleukin‐6 (IL‐6)
receptor CD126 leads to resistance of CLL cells to chemotherapy and worse prognosis
for patients with CLL. In this study, we determine whether autocrine IL‐6 production by
CLL B cells is associated with poor clinical outcome and explore IL‐6‐mediated survival
mechanism in primary CLL cells. Our results demonstrate that higher levels of autocrine
IL‐6 are significantly associated with shorter absolute lymphocyte doubling time, patients
received treatment, without complete remission, advanced Binet stages, 17p/11q
deletion, and shorter time to first time treatment and progression‐free survival. IL‐6
activated both STAT3 and nuclear factor kappa B (NF‐κB) in primary CLL cells. Blocking
IL‐6 receptor and JAK2 inhibited IL‐6‐mediated activation of STAT3 and NF‐κB. Our
study demonstrates that an increased autocrine IL‐6 production by CLL B‐cells are
associated with worse clinical outcome for patients with CLL. IL‐6 promotes CLL cell
survival by activating both STAT3 and NF‐κB through diverse signaling cascades.
Neutralizing IL‐6 or blocking IL‐6 receptor might contribute overcoming the resistance of
CLL cells to chemotherapy. We propose that the measurement of autocrine IL‐6 could be
a useful approach to predict clinical outcome.
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1 | INTRODUCTION
Chronic lymphocytic leukemia (CLL), the most common adult leukemia, is
characterized by the progressive accumulation of phenotypically mature
monoclonal CD5+/CD23+malignant B cells in the peripheral blood, bone
marrow, and lymphoid organs. CLL is heterogeneous disease with a highly
variable clinical course and prognostication at time of diagnosis is mainly
relying on clinicobiological parameters, such as deletions at chromosome
17p or 11q, absence of mutations in the immunoglobulin heavy‐chain
gene (IgVH), expression of protein tyrosine kinase zeta‐associated
protein‐70 (ZAP‐70), the cell surface glycoprotein CD38, and advanced
clinical Binet stages (Caligaris‐Cappio & Ghia, 2008; Chiorazzi, Rai, &
Ferrarini, 2005). Despite improved clinical outcomes using current
chemoimmunotherapy regimens, CLL remains incurable.
Circulating CLL cells are typically long‐lived, however, they rapidly
undergo spontaneous apoptosis in vitro (Liu et al., 2010; Liu, Jia, Wang,
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Farren, et al., 2016), indicating that tumor microenvironmental prosurvi-
val signals in both lymphoid tissue and the circulation play a major role in
preventing CLL cells from apoptotic cell death (Balakrishnan, Burger,
Wierda, & Gandhi, 2009; Liu et al., 2010; Luqman et al., 2008). Many
soluble factors including interleukin (IL) ‐4, ‐6, ‐10, and HMGB1, have
been found in the plasma and tissue microenvironment in patients with
CLL and play important roles in supporting CLL cell survival (Aguilar‐
Hernandez et al., 2016; Antosz et al., 2015; Drennan et al., 2017; Jia et al.,
2014). Inspite of the emergence of new treatment strategies with more
specific targets, there is an increased need for personalized treatment
strategies for patients with CLL.
IL‐6 belongs to a larger family of cytokines and is mainly secreted by
T cells and macrophages to stimulate immune response during infection
(Grivennikov et al., 2009). It has been demonstrated that higher levels of
plasma IL‐6 are positively correlated with worse clinical outcome in
patients with CLL (Fayad et al., 2001) and other cancers (Ebrahimi,
Tucker, Li, Abbruzzese, & Kurzrock, 2004; Meyer et al., 2010). Although
IL‐6 is elevated in the plasma of humans suffering from breast, prostate,
lung, liver, and colon cancer, raised plasma IL‐6 is also seen in a wide
variety of nonmalignant diseases (Heikkila, Ebrahim, & Lawlor, 2008). It
was recently reported that constitutively activated nuclear factor kappa
B (NF‐κB) in CLL cells induces the production of IL‐6 which further
enhances B‐cell receptor and JAK2/STAT3 activation (Rozovski et al.,
2017). IL‐6/JAK/STAT3 form a feed‐forward loop which drives tumor-
igenesis and metastasis (Chang et al., 2013). Many types of cancer cells
secrete IL‐6 due to constitutive activation of STAT3 or NF‐κB (Rozovski
et al., 2017; Yu, Pardoll, & Jove, 2009). Autocrine and paracrine IL‐6
further maintains STAT3 and NF‐κB activation through direct or indirect
signal pathways (Iliopoulos, Hirsch, & Struhl, 2009; Lesina et al., 2011;
Yang et al., 2007). Once activated, both transcription factors regulate
gene expression with significant upregulation of genes involved in
survival, proliferation, and immunosuppression in cancer cells. However,
the precise mechanism by which IL‐6 activates both STAT3 and NF‐κB
are elusive.
Autocrine IL‐6 plays a crucial role in carcinogenesis and cancer
progression in different types of cancer cells (Fukuda et al., 2011;
Gao et al., 2007). We previously reported that IL‐6 membrane‐bound
receptor CD126 surface expression was found in all CLL cases and
positively correlated with the levels of in vivo constitutive STAT3
activity and resistance of CLL cells to chemotherapy. Blocking CD126
using tocilizumab sensitized CLL cells to chemotherapy (Liu, Jia,
Wang, Farren, et al., 2016). In the current study, we aimed to
determine whether the levels of autocrine IL‐6 have prognostic value
in patients with CLL. Using both STRING database prediction and
experimental approaches, we explored the possible link between IL‐
6‐mediated activation of STAT3 with NF‐κB in CLL cells.
2 | MATERIALS AND METHODS
2.1 | Patients, CLL cell separation, culture
The National Research Ethics Service, East London and the City HA
Local Research Ethics Committee approved nondiagnostic analyses, and
written informed consent was obtained (REC reference 07/Q0604/34;
Farren et al., 2015; Liu, Jia, Wang, Farren, et al., 2016). Patients with
CLL (n = 71) with a lymphocyte count greater than 50 × 109/L were
enrolled in this study and all these cases were either untreated (n =25)
or had not received chemotherapy or steroids for over 6 months.
Peripheral blood mononuclear cells (PBMC) were isolated by density‐
gradient centrifugation over Ficoll‐Paque (GE Healthcare, Hatfield, UK).
In all samples, the dual CD19+/CD5+ B‐CLL cells were confirmed to
represent more than 95% of the PBMCs. Freshly isolated CLL cells were
suspended in RPMI‐1640 medium containing 10% fetal bovine serum
and 2 mM L‐glutamine (Invitrogen, Carlsbad, CA) at a density of 5 × 106
cells/ml and cultured at 37°C in a humidified incubator with 5% CO2.
The datasets used or analyzed during the present study are available
from the corresponding author on reasonable request.
2.2 | Treatment of CLL cells
To activate STAT3 or RelA, CLL cells were incubated with 10 ng/ml of
recombinant human IL‐6 (Novartis Pharma AG, Basel, Switzerland). To
inhibit STAT3 or RelA activity, CLL cells were treated with 10 µg/ml anti‐
IL‐6R antibody (MRA; Chugai Pharmaceutical Co. Ltd., Tokyo, Japan),
10 µM AG490 (Sigma‐Aldrich, Dorset, UK), or 10 µM Wortmannin
(Sigma‐Aldrich, Dorset, UK), respectively, for the indicated time periods.
Supernatants were collected for autocrine IL‐6 production assays and the
cells were used for flow cytometry and western blot analysis.
2.3 | Measurement of autocrine production IL‐6
Fresh CLL cells were isolated immediately after phlebotomy.
Percentages of CLL B‐cells were determined by flow cytometry after
stained with PerCP‐CY5.5‐conjugated anti‐CD19 antibody. If CLL
samples contain >95% CD19 positive cells, cells will be directly used
for IL‐6 autocrine assay. For samples with <95% CD19 positive cells,
CLL B cells will be positively selected by B‐cell isolation kit (Miltenyi
Biotec, Woking, UK.; Supporting Information Figure 1 a,b). A total of
5 × 106/ml cells were cultured for 24 hr (or for the indicated times)
with or without treatment, the supernatants were collected and
stored at −80°C until assayed. Autocrine production of IL‐6 in the
supernatants was measured by the enzyme‐linked immunosorbent
assay according to the manufacturer's instructions (R&D Systems,
Minneapolis, MN) with medium alone as the baseline control. The
wells with medium alone did not have measurable levels of either IL‐
6. The concentration of IL‐6 in the patient samples was calculated
against a standard curve. For the samples treated with IL‐6, the
concentrations of added IL‐6 in control wells were subtracted from
the values in test conditions (Liu, Jia, Wang, Wang, et al., 2016).
2.4 | Caspase‐3 activity assay
Cytosolic proteins (50 µg) were diluted to 90 µl with fluorogenic assay
buffer (20mM HEPES‐KOH; pH 7.4; 10mM dithiothreitol, 10% sucrose;
1.0mM ethylenediaminetetraacetic acid A; 0.1% CHAPS). The reaction
was initiated by addition of 10 µl of 400µM (final concentration was
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40µM) fluorescent substrate Ac‐DEVE‐AFC (Merck‐Calbiochem, Not-
tingham, UK) for the caspase‐3 activity. The cleavage reaction was carried
out at 37°C for 15min. The fluorescence at 400/505 nm was measured
with a BMG LABTECH POLARstar OPTIMA Microplate Reader
(Offenburg, Germany; Liu, Agarwal, Gribben, et al., 2008).
2.5 | Differential detergent fractionation for
cellular proteins
Differential detergent fractionation involves sequential extraction of cells
using detergent‐containing buffer separating cellular proteins into distinct
compartments. To extract the cytosolic fraction (fraction 1), CLL cells
were suspended into buffer 1 containing 0.02% digitonin and incubated
on ice for 10min. After centrifugation at 8,000 rpm for 2min, the
cytosolic extracts were transferred into eppendorf tubes. The pellets
were washed with buffer 1 to reduce cytosolic protein contamination.
Fraction 2 proteins (mitochondria and membranous organelles) were
extracted with buffer 2 containing 0.5% Triton X‐100. After washing with
buffer 2 twice, fraction 3 nuclear proteins were directly extracted with
NuPAGE® LDS Sample Buffer (Invitrogen, Carlsbad, CA) and heated to
100°C for 5min. Identification of cellular protein fractions was performed
by western blot analysis using specific antibodies: LDH for cytosolic, COX
IV for mitochondrial, and Rb for nuclear proteins (Jia et al., 2014).
2.6 | Western blot analysis
Proteins were extracted with CelLyticTM M Cell Lysis Reagent
(Sigma‐Aldrich, Dorset, UK) supplied with protease and phosphatase
inhibitor cocktails (Sigma‐Aldrich, Dorset, UK). Proteins were mixed
with NuPAGE LDS Sample Buffer (Invitrogen, Carlsbad, CA) and
boiled for 5min before analysis by western blot analysis. Proteins
were subjected to 4–20% NuPAGE gels (Invitrogen) and transferred
onto polyvinylidene fluoride (PVDF) membrane (Sigma‐Aldrich,
Dorset, UK) at 20 V for 1 hr by semidry transfer. PVDF membrane
was blocked with 5% nonfat milk in TBST for 1 hr and then incubated
with primary antibodies overnight at 4°C against the following
targets: Bcl‐2 (100), RelA (NF‐κB p65, F‐6), Bcl‐XL (H‐5), Bax (2D2),
Survivin (D‐8), and LDH (H‐10) (Santa Cruz Biotechnology, Inc.,
Dallas, TX); β‐actin (AC‐74) (Sigma‐Aldrich, Dorset, UK); p‐RelA
(phospho‐NF‐κB p65‐Ser536), p‐STAT3 (phosphor‐STAT3‐Tyr705),
p‐AKT, AKT, Mcl‐1, and Rb antibodies (Cell Signaling Technology‐
New England Biolabs, Hitchin, UK). Bound antibodies were detected
using appropriate horseshoeradish peroxidase‐conjugated secondary
antibodies and visualized by GeneSnap (SynGene, Cambridge, UK)
after adding ECL plus (GE Healthcare Life Science, Hatfield, UK).
2.7 | Immunofluorescence staining
CLL cells were fixed and permeabilized on slides with Cytofix/Cytoperm
reagents (BD Biosciences, Franklin Lakes, NJ) and blocked with a buffer
consisting of 0.1% saponin and 5% donkey serum. Cells were stained with
either monoclonal anti‐p‐RelA antibody (at 1:100 dilutions; Cell Signaling
Technology, Danvers, MA) or monoclonal anti‐RelA antibody (at 1:20;
Santa Cruz Biotechnology, Inc., Dallas, TX) for 1 hr at room temperature.
After washing with Tris‐buffered saline Tween20 (TBST), cells were
incubated with Alexa‐Fluor 488 conjugated antimouse secondary anti-
body at a 1:100 dilution (Invitrogen, Carlsbad, CA). Slides were washed
for three times with TBST, stained with 50 ng/ml 4′,6‐diamidino‐2‐
phenylindole, air‐dried at 4°C in the dark, and mounted in ProLong® Gold
antifade reagent (Invitrogen, Carlsbad, CA) before being viewed under an
Olympus BX40 fluorescence microscope (Artisan Scientific Corporation,
Champaign, IL; Jia et al., 2014).
2.8 | Determining NF‐κB DNA binding activity by
electrophoretic mobility shift assay
NF‐κB DNA binding activity was assessed using the electrophoretic
mobility shift assay (EMSA). This assay is based on the fact that DNA‐
protein complexes migrate slower than nonbound DNA in native
polyacrylamide, resulting in a “shift” in the migration of the labeled
DNA band. Nuclear protein–DNA complexes were extracted by NE‐
PER® Nuclear and Cytoplasmic Extraction Reagents (Pierce‐Thermo
Scientific, Waltham, MA). Double‐stranded NF‐κB consensus oligonucleo-
tides 5′‐AGT TGA GGG GAC TTT CCC AGG C‐3 and 3′‐TCA ACT CCC
CTG AAA GGG TCC G‐5′ (Santa Cruz Biotechnology, Inc., Dallas, TX)
containing a putative binding site for NF‐κB were end‐labeled with biotin
using Biotin 3′ End DNA Labeling Kit (Pierce‐Thermo Scientific, Waltham,
MA). Bands were detected by “The Light ShiftTM Chemiluminescent
EMSA kit” (Pierce‐Thermo Scientific, Waltham, MA) using a nonisotopic
method to detect DNA‐protein interactions. Biotin end‐labeled DNA
duplex of NF‐κB was incubated with the nuclear extracts (10 µg nuclear
proteins). After the reaction, the DNA–protein complexes were subjected
to a 6% DNA retardation gel (Invitrogen, Carlsbad, CA) and transferred
to a positively charged nylon membrane (Pierce‐Thermo Scientific). After
transfer, the membrane was immediately cross‐linked for 15min on a
Gene Flash UV transilluminator (Syngene, Cambridge, UK). A chemilu-
minescent detection method utilizing a luminol/enhancer solution and a
stable peroxide solution (Pierce‐Thermo Scientific, Waltham, MA) was
used as described by the manufacturer, and membranes were exposed
under using the Luminescent Image Analyzer (FujiFilm, Tokyo, Japan) for
visualization (Jia, Gopinathan, Sukumar, & Gribben, 2012).
2.9 | Knockdown specific mRNAs by transfection
of siRNAs
Human STAT3 (sc‐29493), RelA, JAK2, and AKT siRNA, (Santa Cruz
Biotechnology, Inc., Dallas, TX) consisted of a pool of 3 target‐specific 19–
25 nt siRNAs designed to knock down gene expression. Fresh primary
CLL cells (5 × 107/ml) were suspended in 100µl of Human B Cell
Nucleofector (R) reagent (Lonza, Basel, Switzerland) and 2µg of STAT3
siRNA or control siRNA A was added into the mixture. The transfection
was performed using NucleofectorTM II apparatus with the program U‐
015 (Lonza, Basel, Switzerland). Transfection efficiency and cell death
were determined by flow cytometry after transfection with PMAX‐GFP
plasmid for 24 hr (Liu, Jia, Wang, Wang, et al., 2016). Protein expression
was determined at indicated times.
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2.10 | Flow cytometry assays for cell death and
mitochondrial function
Cell viability was determined by propidium iodide (PI) dye exclusion.
After treatment, cells were incubated with 10 µg/ml PI (Sigma‐
Aldrich, Dorset, UK) and the integrity of cell membrane was
measured by flow cytometry using a FACS Canto (Becton Dickinson,
Oxford, UK). To determine the mitochondrial membrane potential
(ΔΨm), cells were stained with 40 nM tetramethylrhodamine methyl
ester (TMRM; Invitrogen) at 37°C for 15min and changes in ΔΨm
were measured on the FH2‐H channel (Liu, Agarwal, Movasaghi,
et al., 2008). To measure the production of reactive oxidative species
(ROS), cells were stained with 40 µM dihydroethidium (HE; Poly-
science‐Park Scientific, Northampton, UK) at 37°C for 15min and
increases in ROS production were measured on the FH3‐H channel
(Liu, Agarwal, Movasaghi, et al., 2008). For mitochondrial cytochrome
c release, cells were permeabilized or fixed as previously reported
(Liu et al., 2010) and washed three times with phosphate buffer
saline (PBS). Cells were incubated with 20 µl of PE‐conjugated anti‐
cytochrome c mAb (Santa Cruz Biotechnology, Inc., Dallas, TX) for
1 hr at room temperature in the dark. Before analysis by flow
cytometry, cells were washed once in PBS.
2.11 | Analysis of protein−protein associations by
STRING
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING;
http://string‐db.org/) is a precomputed database for the exploration and
analysis of protein–protein associations. The associations are derived
from high‐throughput experimental data, mining of databases and
literature, analyses of coexpressed genes and also from computational
predictions, including those based on genomic context analysis. STRING
employs a unique scoring framework based on benchmarks of the
different types of associations against a common reference set, to
produce a single confidence score per prediction (Lee et al., 2011;
Rakshit, Rathi, & Roy, 2014).
2.12 | Statistical analysis
Data are shown as either mean ± standard deviation or median with
interquartile range when variation was high. Significant differences
between groups were analyzed using Student's t test. Pearson's
correlation coefficient method was used to analyze the linear correlation
between two groups. Outcomes, measured from date of diagnosis to
event occurrence or date of the last follow‐up, were progression‐free
survival, the event being a relapse after first treatment, and time to first
time treatment (TTFT), the event of patients with CLL receive first
treatment after diagnosis. All p < 0.05 were considered statistically
significant. *, **, and *** indicate p<0.05, 0.01, and 0.001, respectively (Jia
et al., 2014). Statistical analyses were performed using IBM SPSS
(London, UK) version 22 for Windows and GraphPad Prism version 5.03.
The levels of plasma IL‐6 were analyzed using the statistical
software package X‐tile (Yale University; Camp, Dolled‐Filhart,
& Rimm, 2004) enabling cut points to be determined for markers
without validated normal ranges. The X‐tile divides patients into two
independent data sets (test and validation), in a 1:2 ratio, determines
optimal cut point(s) for each marker in the test set and applies them
to the validation set (Camp et al., 2004). In univariate analysis,
Kaplan–Meier survival curves were generated using these cut points
and p‐values, HR and 95% CIs generated using a log‐rank test. The
Cox proportional hazards model was used to identify the indepen-
dent prognostic factors (Greaves et al., 2013; Yu et al., 2014).
3 | RESULTS
3.1 | The significant impact of autocrine IL‐6
production on clinical outcomes in patients with CLL
Autocrine IL‐6 is intrinsic to CLL cells themselves and may better
reflect the underlying biology of different prognostic CLL subgroups.
The association between levels of autocrine IL‐6 with each
prognostic subgroup was analyzed in 71 CLL samples. In vivo, CLL
cells are typically long‐lived which can be evaluated clinically by the
lymphocyte doubling time (LDT). The patients with a longer LDT (>12
months) will have a better response to the treatment and a less
aggressive clinical course (Liu, Jia,Wang, Farren, et al., 2016). Patients
with CLL with a longer LDT (>12 months) have significantly lower
levels of autocrine IL‐6 compared to the cases with a shorter LDT
(<12 months; Figure 1a). Similarly, patients with CLL with not yet
required treatment have significantly lower average autocrine IL‐6
production than previously been treated patients (Figure 1b). In vitro
studies showed that the level of autocrine IL‐6 positively correlated
with cell viability and negatively correlated with chemo‐sensitivity.
This suggests that the higher levels of IL‐6 protect CLL from
spontaneous and chemotherapy‐induced cell death (Supporting
Information Figure 2). To evaluate whether the levels of autocrine
IL‐6 associated with patient's response to clinical treatment, patients
were divided into two groups: achieving a complete response (CR)
versus not achieving a CR (ie, a partial response, stable disease, and
progressive disease). The levels of autocrine IL‐6 in the non‐CR group
were significantly higher than in the CR group (Figure 1c), IL‐6 was
significantly higher in Binet stage B/C versus stage A, and 17p‐/11q‐
versus non 17p‐/11q‐cytogenetics. There were no statistically
significant differences of levels of IL‐6 in CD38+ versus CD38‐ and
ZAP70 + versus ZAP70‐subgroups (Figure 1d).
To further explore the correlation between autocrine IL‐6
production and clinical prognosis, we determined the association
between autocrine IL‐6 levels with the TTFT using categorical log‐rank
analysis. The cut‐off point for IL‐6 (≥9.35 pg/ml) was obtained using
the X‐tile software. Patients with CLL with lower levels of autocrine IL‐
6 showed a significantly longer TTFT than patients with the higher
levels of IL‐6 subset. The median TTFT in the higher IL‐6 group was 15
years versus 3.2 years in the lower IL‐6 group (Figure 1e). The TTFT is
also significantly associated with other risk factors such as Binet
stages and ZAP‐70 positivity, except CD38 (Supporting Information
Figure 3). The median PFS in patients with lower IL‐6 group was
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15 years versus 5 years in the higher IL‐6 group (Figure 1f). Median
PFS in the stage A group was 15 years compared to 5 years in stage
B/C group (Supporting Information Figure 3), and in the ZAP70‐ group
was 15 years compared to 5 years in the ZAP70 + group, respectively
(Supporting Information Figure 3). Multivariate analysis showed that
the significance of autocrine IL‐6 levels remains after IL‐6
was stratified with all risk factors (Table 1) or a single risk factor
(Table 2). This indicates that levels of autocrine IL‐6 on the prediction
F IGURE 1 The association of autocrine
IL‐6 with clinical outcome in patients with
CLL. Autocrine IL‐6 production was
determined by IL‐6 ELISA kit after 5 × 106/ml
cells were cultured for 24 hr. Levels of
autocrine IL‐6 production were compared in
(a) LDT≥12/12 (n=38) vs. LDT≤ 12⁄12
(n= 34), (b) treated (n=35) vs. untreated
(n= 34) groups, (c) patients with CR (n= 10)
vs. non‐CR (n=25), (d) other prognostic
markers. Data were analyzed by the
Mann–Whitney test. *p<0.05, **p<0.01, and
***p<0.001. NS means not significant. (e)
Time to the first treatment (TTFT) and (f)
Progress‐free survival (PFS) of patients
with CLL based on of patients with low
autocrine IL‐6 (<9.35 pg/ml) and high IL‐6
(>9.35 pg/ml). Cut‐off point was obtained by
the X‐tile software. CLL: chronic lymphocytic
leukemia; CR: complete remission; ELISA:
enzyme‐linked immunosorbent assay; IL‐6:
interleukin 6; LDT: lymphocyte doubling
time [Color figure can be viewed at
wileyonlinelibrary.com]
TABLE 1 Uni‐ and multi‐variate analysis of categorical covariates of TTFT and PFS
Outcome Covariates (cut point)
Univariate analysis Multivariate analysis
HR (95%CI) p HR (95% CI) p
TTFT IL‐6a (>9.35vs.≤9.35) 2.910 (1.461–5.796) 0.002 3.597 (1.27–10.12) 0.015
Stage (B/C vs. A) 3.770 (1.865–7.619) <0.0001 0.751 (0.215–2.620) 0.654
17p11q (+vs.−) 2.072 (1.033–4.155) 0.040 1.711 (0.508–5.763) 0.386
ZAP‐70 (+vs.−) 3.033 (1.270–7.245) 0.012 2.652 (0.843–8.349) 0.095
CD38 (+vs.−) 1.832 (0.908–3.693) 0.091 – –
PFS IL‐6a (>9.35vs.≤9.35) 2.910 (1.345–6.298) 0.007 3.581 (1.017–12.61) 0.047
Stage (B/C vs. A) 4.245 (1.933–9.324) <0.0001 1.246 (0.282–5.499) 0.771
17p11q (+vs.−) 1.992 (0.908–4.371) 0.086 1.571 (0.343–7.201) 0.561
ZAP‐70 (+vs.−) 2.854 (1.009–8.069) 0.048 2.006 (0.528–7.614) 0.307
CD38 (+vs. −) 2.088 (0.957–4.558) 0.065 – –
Note. Covariates that were included in the multivariate analysis were first selected using the Enter and then the backward/forward stepwise.
CI: confidence interval; HR: hazard ratio; PFS: progression‐free survival; TTFT: shorter time to first time treatment.
aCategorical cut‐off points were defined by the X‐tile software, N = 71.
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of clinical prognosis is independent of other prognostic markers. These
findings suggest that the levels of autocrine IL‐6 have clinical utility as
an independent prognostic marker for patients with CLL. However,
this needs to be verified in other independent cohorts.
3.2 | IL‐6 induces NF‐κB and STAT3 activation in
primary CLL cells in vitro
The signaling pathway by which IL‐6 induces STAT3 activation has
been well documented (Akira et al., 1994; Antosz et al., 2015; Zhong,
TABLE 2 Multivariate analysis for IL‐6 on clinical outcome
Covariate
TTFTa PFSa
HR; 95% CI p Value HR; 95% CI p Value
Stage 2.706 (1.257–5.823) 0.011 3.231 (1.386–7.536) 0.007
IL‐6 2.361 (1.081–5.160) 0.031 2.171 (0.922–5.109) 0.076
17p11q 1.409 (0.661–3.001) 0.374 1.382 (0.597–3.199) 0.450
IL‐6 2.543 (1.198–5.398) 0.015 2.599 (1.134–5.957) 0.024
ZAP‐70 2.394 (0.977–5.868) 0.056 2.134 (0.720–6.326) 0.172
IL‐6 2.885 (1.141–7.296) 0.025 2.957 (0.932–9.384) 0.066
CD38 1.517 (0.742–3.101) 0.254 1.788 (0.806–3.969) 0.153
IL‐6 3.091 (1.488–6.421) 0.002 2.886 (1.288–6.466) 0.010
Note. Effect of IL‐6 on clinical outcome was adjusted individually by each risk factor.
CI: confidence interval; HR: hazard ratio; IL‐6: interleukin 6; PFS: progression‐free survival; TTFT: shorter time to first time treatment; ZAP‐70:
zeta‐associated protein‐70.
aNumber of cases = 71.
F IGURE 2 IL‐6‐mediated activation of
NF‐κB and STAT3. (a) IL‐6‐induced
phosphorylation of RelA and STAT3.
Primary CLL cells were incubated with
10 ng/ml IL‐6 and cells were collected for
western blot analysis at indicated times.
Numbers on the bottom are patients ID.
(b) Localization of P‐RelA and RelA.
Primary CLL cells were incubated with
IL‐6 for 4 hr. Cells on slides were stained
with either P‐RelA or RelA antibodies,
respectively. DAPI indicates nucleus
location. (c) IL‐6‐mediated RelA binding to
DNA as detected by EMSA. (d) Statistical
analysis of IL‐6‐induced binding between
RelA and DNA. CLL: chronic lymphocytic
leukemia; DAPI: 4′,6‐diamidino‐2‐
phenylindole; EMSA: electrophoretic
mobility shift assay [Color figure can be
viewed at wileyonlinelibrary.com]
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Wen, & Darnell, 1994). However, the mechanisms by which IL‐6‐
mediated activation of NF‐κB is still elusive. We found IL‐6 induces
time‐dependent upregulation of both p‐RelA (NF‐κB‐p65) and
p‐STAT3 in primary CLL cells as detected by western blot analysis
(Figure 2a). Immunofluorescent staining showed that the p‐RelA is
weakly expressed in the cytosol of CLL cells in the resting stage. After
stimulation with IL‐6, increased p‐RelA mainly localized in the nucleus
of CLL cells. In contrast, non‐phosphorylated RelA was localized in the
nucleus in both the control and IL‐6 treated CLL cells (Figure 2b). To
further confirm whether IL‐6 induces NF‐κB activation, NF‐κB DNA
binding activity was determined by EMSA. IL‐6 stimulation signifi-
cantly increased NF‐κB DNA binding activity, as detected in three
cases of primary CLL cells (Figure 2c,d). These results indicate that IL‐6
not only activates STAT3 but also stimulates NF‐κB, suggesting that
the NF‐κB is involved in IL‐6‐mediated signaling network.
3.3 | Database prediction of functional associations
between proteins in IL‐6 signaling pathway
The causal relationship between IL‐6‐mediated activation of STAT3
and NF‐κB is unclear. We established a theoretical IL‐6 signaling
network using the online STRING program. First, five well‐known
tumor survival signaling proteins, IL‐6, JAK2, AKT1, STAT3, and RelA
were chosen to predict their functional associations (Rakshit et al.,
2014). All of these proteins are involved in the cellular response to
cytokine stimulus (showing in the yellow color) and four of them
(except RelA) are responsible for regulation of reactive oxygen
species (ROS) biosynthetic process (in the red color; Figure 3a). After
randomly expanded this network, PIK3CA, PIK3CB, and PI3KCD,
which activate AKT, bridge the link between JAK2 and AKT, are
shown in the network. MTOR, which is a molecule in PI3K/AKT/
mTOR pathway, has a strong association with JAK2 and STAT3 but a
weak link with IL‐6. Similar to RelA, NFKB1A (p105/50) can also be
activated by IL‐6 (Figure 3b).
The specific actions between proteins were predicted by
STRING (Figure 3c). The stronger specific action was marked as
red color and weaker action as orange color. IL‐6 has the strongest
functional links with both STAT3 and JAK2, including activation,
binding, catalysis, inhibition and posttranslation modification (PTM).
The specific actions between STAT3 and JAK2 are similar to their
own functional links to IL‐6. The specific action of IL‐6 to RelA
includes activation and expression. Although IL‐6‐mediated activa-
tion of STAT3 and AKT also induces gene or protein expression,
their scores of actions on expression are far lower than RelA. The
F IGURE 3 STRING prediction of
functional associations of proteins in IL‐6
signaling pathway. (a) Functional network
of 5 IL‐6 associated signaling molecules; (b)
Expanded network. (c) Prediction of
specific action scores between proteins.
The red color indicates score >0.80 and
orange color shows action scores are at
medium levels. IL‐6: interleukin 6; STRING:
search tool for the retrieval of interacting
genes/proteins [Color figure can be viewed
at wileyonlinelibrary.com]
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association between STAT3 and RelA is only “binding,” suggesting
that these two transcriptional factors may not direct activate each
other.
3.4 | JAK2 and PI3‐K/AKT are required for
IL‐6‐induced RelA activation in CLL
To determine the experimental and biological association between
IL‐6‐mediated NF‐κB activation, the anti‐IL‐6 receptor antibody was
used to block IL‐6 binding to its surface receptor and the JAK2
inhibitor AG490 was used to inhibit JAK2‐mediated signaling. IL‐6‐
mediated phosphorylation of STAT3 and RelA were significantly
decreased after treatment with anti‐IL‐6 receptor antibody or
AG490 (Figure 4a,b). To determine whether STAT3 is involved in
IL‐6‐induced RelA phosphorylation in CLL, the levels of phosphory-
lated STAT3 and RelA were determined by western blot analysis
after knockdown either STAT3 or RelA. Surprisingly, knockdown of
STAT3 did not inhibit p‐RelA expression and similarly knockdown of
RelA had no effect on p‐STAT3 expression (Figure 4c,d). In a good
agreement with STRING prediction on protein–protein association,
our results indicate that STAT3 and RelA do not activate each other
in CLL cells, at least at the early time points after stimulation with
exogenous IL‐6.
It was previously reported that PI3K/AKT are downstream effectors
in IL‐6‐mediated survival signaling pathways (Hideshima, Nakamura,
Chauhan, & Anderson, 2001). Treatment with wortmannin (PI3K
F IGURE 4 Functional analysis of the
IL‐6‐mediated signaling pathway. (a,b)
After IL‐6 receptor was blocked by
anti‐IL‐6 receptor antibody and JAK2 was
blocked by AG490; primary CLL cells were
incubated with IL‐6 for 16 hr. (c,d) STAT3
or RelA was knocked down by transfection
of STAT3 or RelA siRNA, and cells were
incubated with IL‐6. The levels of P‐STAT3
and P‐RelA were determined by western
blot analysis. (e,f) CLL cells were treated
with PI3K inhibitor Wortmannin or AG490
and then incubated with IL‐6 for 16 hr.
(g,h) JAK2 or AKT was knocked down by
transfection of JAK2 or AKT siRNA and
after 24 hr cells were incubated with IL‐6
for 16 hr. Phosphorylation of AKT and
RelA was determined by western blot
analysis. A, C, E, and G are representative
western blot analysis and B, D, F, and H are
statistical analysis of at least three cases
data. Relative expression of
phosphorylated protein was analyzed by
densitometry using actin as control. Data
shown are mean ± SD from at least three
independent experiments. CLL: chronic
lymphocytic leukemia; IL‐6:interleukin 6;
SD: standard deviation
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inhibitor) or AG490 significantly inhibited IL‐6‐mediated phosphoryla-
tion of AKT and RelA in CLL cells (Figure 4e,f). Knockdown of JAK2
inhibited IL‐6‐mediated phosphorylation of AKT and RelA and silencing
AKT significantly decreased IL‐6‐induced RelA phosphorylation (Figure
4g,h). Our results, in a good agreement with the STRING prediction,
demonstrate that IL‐6 mediates NF‐κB activation is dependent, a least
partly, on JAK2‐associated PI3K/AKT signaling pathway.
3.5 | IL‐6 increases mitochondrial STAT3
expression and preserves mitochondrial function
Recent studies have revealed a novel role of p‐STAT3S727 in sustaining
mitochondrial electron transport chain (ETC) activity, which regulates
mitochondrial metabolic function and cell survival in normal and
malignant cells (Gough et al., 2009;Wegrzyn et al., 2009). We determined
whether mitochondrial STAT3 is involved in the improved CLL cell
survival mediated by IL‐6. STAT3 protein was detected in cytoplasmic,
mitochondrial and nuclear fractions (Figure 5a). Stimulation by IL‐6
increased expression of STAT3 in the mitochondrial fraction (Figure 5b).
We previously reported that spontaneous apoptosis of CLL cells in vitro
is via a mitochondria/caspase‐dependent pathway which involves ROS
generation, ΔΨm depolarization, and cytochrome c release from
mitochondria, resulting in activation of caspase‐3 (Liu, Jia, Wang, Wang,
et al., 2016). CLL cells treated with IL‐6 showed reduced ROS generation,
ΔΨm depolarization, cytochrome c release, and caspase‐3 activity
(Figures 5c–f). Inhibition of JAK2 by AG490 significantly diminished the
protective roles of IL‐6 on the mitochondria/caspase‐dependent apopto-
tic pathway (Figures 4c–f). Expression of Mcl‐1 and Bcl‐xL is coregulated
by both STAT3 and NF‐κB. Inhibition of either STAT3 or NF‐κB decreases
the expression of Mcl‐1 and Bcl‐xL in CLL cells (Liu, Jia, Wang, Wang,
F IGURE 5 IL‐6 prevents
mitochondria‐dependent apoptosis in
CLL cells. (a) STAT3 intracellular
distribution. Fresh primary CLL cells
were fractionalized into cytoplasm (c),
mitochondria (M) and nucleus (N). STAT3
expression was determined by western
blot analysis. LDH, COX IV, and Rb are
markers for cytoplasm, mitochondria and
nucleus, respectively. (b) IL‐6 induced
phosphorylation of STAT3. (c) ROS
production, (d) Mitochondrial
depolarization, and (e) cytochrome c
release were measured by flow
cytometry. (f) Caspase‐3 activity was
measured by a fluorogenic assay. Data
from A to F are mean ± SD from three
independent experiments. Significant
difference was analyzed by the Student
t‐test. (g) Effect of IL‐6 on expression of
Bcl‐xL, Mcl‐1, Bcl‐2, Bax, and Survivin
was determined by western blot analysis.
(h) CLL cell viability. CLL cells were
incubated with or without IL‐6 for 24 hr.
Cell viability was determined by flow
cytometry after cells were stained with
PI. CLL: chronic lymphocytic leukemia;
IL‐6: interleukin 6; PI: propidium iodidie;
ROS; reactive oxidative species; SD:
standard deviation [Color figure can be
viewed at wileyonlinelibrary.com]
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et al., 2016). It was shown above that IL‐6 increased phosphorylation of
both STAT3 and RelA (Figure 2a). In turn, the activation of STAT3 and
RelA by IL‐6 also increased expression of antiapoptotic protein Bcl‐xL and
Mcl‐1, but not Bcl‐2 and Survivin (Figure 5g). In keeping with increased
expression of antiapoptotic Bcl‐xL and Mcl‐1, stimulation with exogenous
IL‐6 increased in vitro survival rate of CLL cells (Figure 5h), possibly in
vivo as well. These results demonstrate that IL‐6 prevents apoptotic cell
death by multiple mechanisms (Figure 6); (a) activating both STAT3 and
NF‐κB via JAK2/PI3K/AKT axis and therefore upregulation of Bcl‐xL and
Mcl‐1; and (b) promoting STAT3 mitochondrial translocation.
4 | DISCUSSION
In the current study, we report for the first time that higher levels of
autocrine IL‐6 are significantly associated with poor clinical outcomes
in patients with CLL. Levels of autocrine IL‐6 could be used clinically
to predict TTFT and PFS for patients with CLL. Moreover, using both
STRING prediction and experimental approaches, we found that IL‐6
mediates activation of both STAT3 and NF‐κB via JAK2/PI3K/AKT
axis in primary CLL cells.
It has been reported that IL‐6 levels in the plasma are associated
with advanced stage and poor clinical outcome in patients with CLL
(Fayad et al., 2001; Lai et al., 2002). However, the source of IL‐6
production was not specified. In this study, we determined autocrine
IL‐6 production by CLL B cells. In tumor microenvironment, autocrine
or paracrine IL‐6 mediates cell growth, differentiation and cytokine
production through activation of the transcriptional factor STAT3
(Fukuda et al., 2011; Grivennikov et al., 2009; Iliopoulos et al., 2009).
IL‐6 is a critical factor for tumorigenesis, cancer cell survival and
proliferation (Bollrath et al., 2009; Lesina et al., 2011). In the dogma
of inflammation‐associated cancer, the initial source of IL‐6 is from
nonmalignant immune cells (Grivennikov et al., 2009), whereas most
cancer cells can produce IL‐6, so both autocrine and paracrine IL‐6 in
the cancer microenvironment maintain STAT3 and NF‐κB activation
via an IL‐6 positive feedback loop (Iliopoulos et al., 2009; Lee et al.,
2009). Autocrine production of IL‐6 by cancer cells promotes
resistance to cell death: apoptosis‐sensitive cells do not express
IL‐6, whereas high levels of IL‐6 are produced by apoptosis‐resistant
cells in breast cancer (Conze et al., 2001).
We found a strong correlation between autocrine IL‐6 produc-
tion, resistance to apoptosis and clinical prognosis: autocrine IL‐6
levels are variable in CLL, however, high IL‐6 levels are associated
with resistance to spontaneous apoptosis in vitro and a poorer
clinical outcome in patients with CLL. The presence of 17p and/or
11q deletion and the expression of ZAP‐70 or CD38 are all
associated with poorer outcomes (Agrawal et al., 2008; Del Principe
et al., 2006; Dohner et al., 2000; Wierda et al., 2011). Due to data
unavailability of IgVH mutation status of patients with CLL, we were
unable to analyze the association between autocrine IL‐6 and IgVH
mutation. We found that regardless of the biological parameter
studied, all risk‐marker positive patients have higher levels of
autocrine IL‐6 production; furthermore, patients with higher auto-
crine IL‐6 levels have a shorter TTFT and PFS compared to patients
with lower autocrine IL‐6. Only autocrine IL‐6 showed a significant
correlation with TTFT; whereas in univariate analysis for PFS,
autocrine IL‐6 and cytogenetic status showed statistically significant
correlations, which were maintained in multivariate analysis.
Transcriptional factors STAT3 and NF‐κB play crucial roles in
carcinogenesis, cancer cell proliferation and survival (Bollrath et al.,
2009; Espinosa et al., 2010; Iliopoulos et al., 2009; Lesina et al.,
2011). STAT3 and NF‐κB are constitutively active in most cancer
cells in response to autocrine and paracrine signals that are produced
within the tumor microenvironment (Grivennikov & Karin, 2010). We
have previously reported there is marked heterogeneity of in vivo
expression of constitutively activated p‐STAT3 and p‐RelA in CLL
cells, which control autocrine IL‐6 and TNF‐α production, whereas
inhibition of the constitutive activation of STAT3 or RelA results in
decreased production of both IL‐6 and TNF‐α (Liu, Jia, Wang, Wang,
et al., 2016). The functional relationship between STAT3 and NF‐κB
is complex. Knocking down STAT3 decreases nuclear but increases
the cytoplasmic distribution of p‐RelA in prostate cancer cells (Lee
et al., 2009). Whereas NF‐κB can indirectly mediate STAT3 activation
via IL‐6 production (Iliopoulos et al., 2009).
F IGURE 6 Schematic illustration of IL‐6‐mediated activation of
STAT3 and NF‐κB. After engagement with receptor CD126, IL‐6
activates JAK2, which induces diverse signaling pathways: (1)
activates STAT3 by inducing STAT3 phosphorylation, mitochondrial
and nuclear translocation; (2) activates PI3K/AKT axis, which induces
NF‐κB activation. Both activated STAT3 and NF‐κB induce
expression of Bcl‐xL and Mcl‐1. Increased expression and Bcl‐xL and
Mcl‐1 in the mitochondria, together with mitochondrial STAT3,
prevent mitochondria‐dependent apoptosis and promote CLL cell
survival. CLL: chronic lymphocytic leukemia [Color figure can be
viewed at wileyonlinelibrary.com]
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IL‐6 plays an important role in the crosstalk between STAT3 and
NF‐κB in cancer cells, with IL‐6 involved in both STAT3 and NF‐κB
activation, although diverse mechanisms of action have been
reported in different types of cells. Iliopoulos et al reported that
NF‐κB activation in tamoxifen‐treated MCF10 cells increases IL‐6
secretion and thereby enhances STAT3 activation (Iliopoulos et al.,
2009). The activated STAT3 then directly activates miR‐21 and
miR181b‐1, which leads to a positive feedback loop for NF‐κB
activation by inhibiting PTEN and CYLD (Iliopoulos, Jaeger, Hirsch,
Bulyk, & Struhl, 2010). In human mammary epithelial cells, IL‐6
enhances STAT3 transcription and expression, with the unpho-
sphorylated STAT3 binding to unphosphorylated NF‐κB. The complex
of unphosphorylated STAT3/NF‐κB can translocate into the nucleus
and regulate target gene expression (Yang et al., 2007). In CLL,
NOTCH1 mutations induce NF‐κB nuclear translocation and activa-
tion (Benedetti et al., 2018). Our data shows IL‐6 can induce NF‐κB
activation in primary CLL cells, with enhanced RelA phosphorylation,
nuclear translocation, DNA binding, and NF‐κB‐mediated IL‐6
production. Predicted by STRING database, STAT3 and NF‐κB bind
but don't activate each other.
We dissected the pathway from IL‐6 to NF‐κB activation by
blockade of the IL‐6 pathway (preventing IL‐6 binding to its receptor
or inhibition of JAK2) and blockade of NF‐κB activation by inhibition
of PI3K/AKT signaling. As expected, either approach leads to a
decrease in IL‐6‐induced p‐AKT and p‐RelA expression. Surprisingly,
knockdown of STAT3 did not affect IL‐6‐induced RelA or AKT
phosphorylation. These results reveal a direct pathway of IL‐6‐
induced NF‐κB activation in CLL cells involving JAK2, PI3K/AKT, and
RelA, but independent of STAT3 (Figure 6).
The inhibition of apoptosis by either STAT3 or NF‐κB activation is
mediated by transcription of several genes that are known to block the
induction of apoptosis, such as Bcl‐2, Bcl‐xL and Mcl‐1 (Dai et al., 2004;
Lesina et al., 2011; Oh et al., 2011; Yu et al., 2009), as well as
upregulation of cytokines, such as IL‐6 (Bollrath et al., 2009; Iliopoulos
et al., 2009). Expression of antiapoptotic proteins Bcl‐xL and Mcl‐1 in
CLL cells is consistent with STAT3 and NF‐κB activation and the survival
of primary CLL cells correlates with their STAT3 and/or NF‐κB
activation status. Survival of CLL cells in vitro also showed a highly
significant correlation with autocrine IL‐6 production.
Targeting IL‐6 has been used therapeutically in a variety of
cancers and nonmalignant conditions (Jones, Scheller, & Rose‐John,
2011; Stone et al., 2012) but it has not been clinical investigated in
CLL. As we previously reported, blocking IL‐6 membrane‐receptor
CD126 using tocilizumab sensitizes CLL cells to chemotherapy (Liu,
Jia, Wang, Farren et al., 2016). We propose that neutralizing IL‐6
could have great therapeutic potential in the improvement of life
expectancy of patients with CLL.
In conclusion, our study demonstrates that higher capacity of
autocrine IL‐6 production of CLL B‐cells is associated with shorter
lymphocyte doubling time, shorter time to the time to first
treatment and shorter progress‐free survival in patients with
CLL. IL‐6 protects CLL cells from apoptosis by activating both
STAT3 and NF‐κB via multiple signaling cascades. In CLL cells,
autocrine IL‐6 provides a measure of the global activity of STAT3
and NF‐κB. As a simple laboratory assay, autocrine IL‐6 measure-
ment may have clinical utility beyond CLL. Furthermore, our data
also indicate a potential therapeutic role for interrupting IL‐6
signaling in CLL.
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